Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

99848

registered interest
date	20/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Motor Neurone Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the availability of augmentative and alternative communication aids for sufferers of motor neurone disease in (a) Surrey and Sussex and (b) England; and if he will make a statement.
tabling member constituency	Woking
tabling member printed	Jonathan Lord
uin	211112
answer	answer is ministerial correction date of answer 27/10/2014 answer text <p>Since April 1 2013 NHS England has been responsible for commissioning Alternative and Augmentative Communication (AAC) aids for patients with complex disability whose needs require specialised assessment, including for patients with motor neurone disease (MND). Commissioning of non-specialised AAC aids is the responsibility of local clinical commissioning groups.</p><p> </p><p> </p><p> </p><p>NHS England has published a service specification for specialised AAC aids that sets out what should be in place for providers to offer evidence-based, safe and effective services and supports equity of access to a nationally consistent, high quality service for patients across the country including in Surrey and Sussex. The specification can be found at:</p><p> </p><p> </p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/06/d01-com-dis-equ-alt-aug-comm-aids.pdf</p><p> </p><p> </p><p> </p><p> </p><p> </p><p>NHS England has identified an additional £22.5 million funding for AAC and Environmental Controls in 2014-15. They have been working closely with the Motor Neurone Disease Association (MNDA) to ensure this funding is equitably distributed across England in a fair and consistent manner. The MNDA are representing all patients on the panel which is reviewing this funding allocation.</p><p> </p><p> </p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 27/10/2014 17:07:49 answering member 1439 label Biography information for Norman Lamb
tabling member	4090 label Biography information for Mr Jonathan Lord

99850

registered interest
date	20/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medical Equipment: West Midlands
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will take steps to ensure the routine commissioning of cough assist machines in the West Midlands.
tabling member constituency	Sutton Coldfield
tabling member printed	Mr Andrew Mitchell
uin	211129
answer	answer is ministerial correction date of answer 27/10/2014 answer text <p>Since 1 April 2013, NHS England has been responsible for commissioning specialised neurological services, which includes services for patients with neuromuscular disorders, such as muscular dystrophy. NHS England has published a neurosciences specification, which sets out what providers must have in place to offer high quality care and treatment for patients.</p><p> </p><p> </p><p> </p><p>The neurosciences service specification describes when patients should be referred to specialist respiratory services and the circumstances in which cough assist devices should be considered. It is available from the NHS England website at this link:</p><p> </p><p> </p><p> </p><p>http://www.england.nhs.uk/wp-content/uploads/2013/06/d04-neurosci-spec-neuro.pdf.</p><p> </p><p> </p><p> </p><p>A copy of this document has also been attached.</p><p> </p><p> </p><p> </p><p>The equipment and respiratory support of cough assist is the commissioning responsibility of clinical commissioning groups, delivered through local specialist respiratory services, according to any local clinical commissioning policy they may have in place.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 27/10/2014 16:43:52 answering member 3918 label Biography information for Jane Ellison attachment 1 file name NHS England neuroscience service specification.pdf title Neurosciences service specification
tabling member	1211 label Biography information for Mr Andrew Mitchell

99854

registered interest
date	20/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Perinatal Mortality: South East
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to reduce the rate of stillbirths in Surrey and Sussex; and if he will make a statement.
tabling member constituency	Woking
tabling member printed	Jonathan Lord
uin	211110
answer	answer is ministerial correction date of answer 27/10/2014 answer text <p>We have made reducing stillbirth an improvement area for the National Health Service in the NHS Outcomes Framework.</p><p> </p><p> </p><p> </p><p>We are advised by NHS England that NHS clinical commissioning groups (CCGs) in Surrey have collectively done significant work relating to perinatal mortality rates, which includes stillbirths. An independent review by the Royal College of Paediatricians and Child Health in 2013 determined that Ashford and St Peter’s Hospitals NHS Foundation Trust (ASPH) was not an outlier with respect to stillbirths. The North West Surrey and Guildford and Waverley CCGs continue to work with ASPH on maternity and paediatric pathways.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 27/10/2014 17:12:14 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	4090 label Biography information for Mr Jonathan Lord

99855

registered interest
date	20/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Blood Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions his Department has had with (a) the Haemophilia Society, (b) the Manor House Group, (c) Tainted Blood, (d) the Hepatitis C Trust and (e) the Contaminated Blood campaign in the last two years.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	211077
answer	answer is ministerial correction date of answer 27/10/2014 answer text <p>In the last two years, the Department has met with the Haemophilia Society about haemophilia services, grant funding for the Society and support for haemophiliacs infected or affected by HIV and/or hepatitis C through historic treatment with NHS-supplied blood products.</p><p> </p><p> </p><p> </p><p>The Department has met with the Hepatitis C Trust about hepatitis C services, grant funding for the Trust and support for individuals infected or affected by hepatitis C through historic treatment with NHS-supplied blood or blood products.</p><p> </p><p> </p><p> </p><p>The Department has met with representatives of the Manor House Group, Tainted Blood and the Contaminated Blood Campaign about support for individuals infected or affected by HIV and/or hepatitis C through historic treatment with NHS-supplied blood or blood products, the scientific and clinical evidence for hepatitis C, and haemophilia services.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 27/10/2014 17:05:12 answering member 3918 label Biography information for Jane Ellison
tabling member	1533 label Biography information for Dame Diana Johnson

99857

registered interest
date	20/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many (a) first-stage payments and (b) second-stage payments have been made from the Skipton Fund to the estates of individuals who contracted hepatitis C following NHS treatment with blood products between 1970 and 1995 but who died before 29 August 2003; what the total amount of money paid out to these estates was; how many total applications for lump sum payments were made by the families and dependants of these victims from 10 January to the end of March 2011; how many applications were refused on the basis that they came in too late; whether his Department has received any representations from (i) the families of victims, (ii) campaign groups and (iii) the Skipton Fund or Caxton Foundation about the time available to apply.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	211080
answer	answer is ministerial correction date of answer 27/10/2014 answer text <p>The following table sets out the number of payments and total paid out by Skipton Fund Ltd to the estates of individuals who contracted hepatitis C through treatment with NHS supplied blood or blood products prior to 1991 and who died prior to 29 August 2003.</p><p> </p><p> </p><p> </p><table><tbody><tr><td rowspan="2"><p> </p></td><td colspan="2"><p>(a) Stage 1</p></td><td colspan="2"><p>(b) Of whom have also received Stage 2*</p></td></tr><tr><td><p>Number of payments</p></td><td><p>Total cost (£)</p></td><td><p>Number of payments</p></td><td><p>Total cost (£)</p></td></tr><tr><td><p>For all individuals</p></td><td><p>472</p></td><td><p>9,440,000.00</p></td><td><p>258</p></td><td><p>12,900,000.00</p></td></tr><tr><td><p>Comprising individuals with a bleeding disorder treated with plasma derived products</p></td><td><p>441</p></td><td><p>8,820,000.00</p></td><td><p>236</p></td><td><p>11,800,000.00</p></td></tr><tr><td><p>And individuals treated with a whole blood transfusion</p></td><td><p>31</p></td><td><p>620,000.00</p></td><td><p>22</p></td><td><p>1,100,000.00</p></td></tr></tbody></table><p> </p><p>*Stage 2 payment is made for individuals who received a stage 1 payment and progressed to more severe hepatitis C related disease.</p><p> </p><p> </p><p> </p><p>There were 81 such applications before 31 March 2011. However, the deadline initially set of 31 March 2011 was for registrations with the Skipton Fund and not completed applications. No applications have been refused to date for missing the deadline.</p><p> </p><p> </p><p> </p><p>The Department received representations from campaign groups and families of deceased individuals in relation to the deadline, and worked with the Skipton Fund in 2011 to agree that any late registrations would be processed, provided the individual registering had good reason for the late registration.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 27/10/2014 17:01:00 answering member 3918 label Biography information for Jane Ellison
tabling member	1533 label Biography information for Dame Diana Johnson

99858

registered interest
date	20/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Blood: Contamination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether benefits an individual receives are taken into account when deciding an individual's eligibility for discretionary financial payments from the (a) Caxton Foundation, (b) Macfarlane Trust and (c) Eileen Trust.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	211078
answer	answer is ministerial correction date of answer 27/10/2014 answer text <p>When deciding an individual's eligibility for discretionary financial payments, the Caxton Foundation, Macfarlane Trust and Eileen Trust, all take benefits into account as part of overall household income.</p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 27/10/2014 17:03:20 answering member 3918 label Biography information for Jane Ellison
tabling member	1533 label Biography information for Dame Diana Johnson

99861

registered interest
date	20/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the basis is for the distinction between Stage 1 and Stage 2 of hepatitis C virus which determines the amount of support sufferers of the condition who contracted the virus following NHS treatment with blood products are entitled to; and what medical and expert advice his Department sought before establishing this distinction.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	211083
answer	answer is ministerial correction date of answer 27/10/2014 answer text <p>The decision that there should be a two-stage ex-gratia payment system was taken when the scheme was first established in 2003-04. An initial ‘stage 1’ lump sum payment was made in respect of chronic infection with hepatitis C, with a second ‘stage 2’ lump sum payment when people reached a more advanced stage of illness. The Department sought the advice of an independent group of experts regarding a medical trigger for the higher payment that could reliably be diagnosed with non-invasive tests that were available nationwide. The advice received was that the second lump sum payment should be triggered following a diagnosis of cirrhosis or liver cancer, or if a person had received a liver transplant.</p><p> </p><p> </p><p> </p><p>In addition, as a result of the 2010 expert review, a further condition was added to those conditions that triggered eligibility for the second stage payment, namely hepatitis C-associated B-cell non-Hodgkins Lymphoma.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 27/10/2014 17:11:03 answering member 3918 label Biography information for Jane Ellison
tabling member	1533 label Biography information for Dame Diana Johnson

99862

registered interest
date	20/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Babies: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the cost would be of immediately screening all newborn babies for MCAD deficiency.
tabling member constituency	Pendle
tabling member printed	Andrew Stephenson
uin	211014
answer	answer is ministerial correction date of answer 27/10/2014 answer text <p>This information is not held centrally. All newborn babies are screened currently for four serious but rare conditions, including Medium-chain acyl-CoA dehydrogenase deficiency (MCADD). This is part of the postnatal pathway and is paid for as part of the Maternity Pathway Payment (MPP). The cost for screening MCADD is not identified separately within the MPP.</p><p> </p><p> </p><p> </p><p>The NHS Newborn Bloodspot Screening Programme in England routinely offers newborn screening for phenylketonuria, congenital hypothyroidism, sickle cell disease, cystic fibrosis and MCADD. Newborn screening in England is offered between 5 and 8 days after the baby is born. The midwife takes a small sample of blood droplets from the baby’s heel for testing on a blood spot card.</p><p> </p><p> </p><p> </p><p>With early detection further diagnostic testing and early treatment can then be provided and avoid any unnecessary wait and help improve and prevent severe disability.</p><p> </p><p> </p><p> </p><p>The UK National Screening Committee have recommended extending the newborn bloodspot screening programme in 2015 to include screening for maple syrup urine disease, homocystinuria, glutaric acidaemia type 1 and isovaleric acidaemia.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 27/10/2014 17:20:12 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	4044 label Biography information for Andrew Stephenson

99864

registered interest
date	20/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Strokes: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment (a) his Department and (b) the NHS has made of a potential connection between chicken pox and stroke in children.
tabling member constituency	Hartlepool
tabling member printed	Mr Iain Wright
uin	211017
answer	answer is ministerial correction date of answer 27/10/2014 answer text <p>The Department has made no assessment of the link between chicken pox and stroke in children; research by the London School of Hygiene and Tropical Medicine and University College London in 2013, suggested that children who experience chickenpox are at a four‐fold increased risk of ischaemic stroke in the subsequent six months, although the study recognised that this was still only a small absolute stroke risk, due to the low baseline incidence of paediatric stroke.</p><p> </p><p>Research by the School of Hygiene and Tropical Medicine, funded by the National Institute for Health Research and the Stroke Association has identified that a patient’s risk of stroke significantly increased following shingles.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 27/10/2014 17:13:45 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	1478 label Biography information for Mr Iain Wright

99867

registered interest
date	20/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hospitals: Parking
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to ensure that hospitals follow the updated guidelines on hospital car parking charges.
tabling member constituency	Harlow
tabling member printed	Robert Halfon
uin	211028
answer	answer is ministerial correction date of answer 27/10/2014 answer text <p>The Department of Health published new National Health Service patient, visitor and staff car parking principles on 23 August 2014. These principles, widely welcomed by a range of charities and organisations representing patients’ interests, made it clear that NHS trusts should publish:</p><p> </p><p> </p><p> </p><p>- their parking policy;</p><p> </p><p>- their implementation of the NHS car parking principles;</p><p> </p><p>- financial information relating to their car parking arrangements; and</p><p> </p><p>- summarised complaint information on car parking and actions taken in response.</p><p> </p><p> </p><p> </p><p>In line with our policy of making all key information transparently available to patients, our expectation is that this information will be displayed prominently on trust websites so that patients and the public can hold the NHS locally to account where unfair parking charges and practices remain in place.</p><p> </p><p> </p><p> </p><p>In addition, we will be collecting information about NHS compliance with these principles via the next round of the Patient Led Assessments of the Care Environment data collection and the results will be published so that patients can identify those trusts who are falling short.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter grouped question UIN 211029 question first answered 27/10/2014 16:57:30 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	3985 label Biography information for Robert Halfon